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Objective: The objectives of the study were to clarify the correlation between the expression 
of secreted protein acidic and rich in cysteine (SPARC) and HPV-status, and to determine 
the prognostic value of SPARC-expression in oropharyngeal squamous cell carcinoma 
(OPSCC) patients. 
Methods: Fifty-three formalin-fixed and paraffin-embedded tissues were obtained from 
patients with OPSCC who underwent curative treatment. The SPARC protein was detected 
by immunohistochemistry. SPARC-expression level was divided into two categories, 
SPARC-High and SPARC-Low, according to the staining index. 
Results: Twenty-two out of the 53 OPSCC patients were HPV-positive. There was no 
significant correlation between the HPV-status and SPARC-expression level. Multivariate 
Cox proportional hazards regression analysis revealed that the HPV-status and 
SPARC-expression are independent prognostic indicator of favorable and unfavorable 
overall survival (OS) (p = 0.021 and p = 0.012), respectively. For disease-free survival, the 
HPV-status was the only predictive factor (p = 0.022). After stratification by the HPV-status, 
high SPARC-expression was a significant predictor of poor OS in HPV-negative OPSCC 
patients using Kaplan-Meier analysis and the log-rank test (p = 0.014). Ten out of 28 
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SPARC-Low patients relapsed, among which 6 patients (60%) were salvaged. However, 14 
out of 25 SPARC-High patients relapsed, and only 3 patients (21.4%) were salvaged. 
Conclusion: SPARC-expression is an indicator of the prognosis in terms of OS independent 
of HPV-infection. HPV-negative patients with SPARC-Low show survival as favorable as 
HPV-positive patients, probably because of their higher salvage rate after relapse than 
SPARC-High patients. 
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Infection with high-risk human papillomavirus (HPV) has been etiologically linked to 
the development of head and neck squamous cell carcinomas, particularly carcinomas that 
arise in the oropharyngeal region. Patients with HPV-positive oropharyngeal squamous cell 
carcinoma (OPSCC) are characterized by an epidemiologic, demographic, and clinical profile 
that deviates from that of HPV-negative patients [1]. The most important difference is 
related to the prognosis, which is markedly better for patients with HPV-positive tumors 
compared to their HPV-negative counterparts [2]. 
To date, OPSCC patients have presented with few prognostic markers targetable for 
improving prevention and treatment strategies. The HPV-status is closely associated with 
the prognosis of OPSCC patients and there is significant heterogeneity in outcomes of 
HPV-negative OPSCC patients [3]. However, no other reliable biomarkers have been found. 
If new biomarkers, that can help determine the prognosis and survival of OPSCC patients, 
can be detected, they may help avoid both over- and under-treatment of OPSCC patients, 
resulting in improvements in the survival and quality of life of patients with this disease. 
Secreted protein acidic and rich in cysteine (SPARC) has attracted marked interest as 
a tumor-associated protein for its diverse actions and complex functions. The increased 
expression of SPARC is associated with a highly aggressive tumor phenotype in melanomas 
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and gliomas, as supported by previous functional studies [4], [5], [6], [7]. However, other 
studies reported that SPARC acts as a tumor suppressor in pancreatic adenocarcinoma, 
acute myeloid leukemia, and ovarian and colorectal carcinomas [8], [9], [10], [11]. Actually, 
recent studies revealedthat SPARC mediates the interaction between cells and the 
extracellular environment as a matricellular protein, and upregulating its expression 
enhances chemosensitivity [12]. Functions of SPARC  are elucidated in other cancers, but 
there are no report about relations between OPSCC and SPARC, and viral carcinogenesis 
and SPARC. The role of SPARC-expression in OPSCC remains to be clarified.  
Here, we examined the expression of SPARC protein in OPSCC tissues. The purposes 
of the current study were to explore the correlation between SPARC-expression and the 




Materials and Methods 
Patients and tissue samples. 
Fifty-three specimens were obtained from patients with OPSCC who underwent 
curative treatment such as surgery and/or radiotherapy with or without chemotherapy at 
Kanazawa University Hospital between 1991 and 2012. All specimens were fixed in 10% 
neutral formalin and embedded in paraffin, and then clinically and histopathologically 
diagnosed. All patients were staged according to the TNM staging system [13] based on 
initial radiologic imaging evaluation and endoscopic observation. The follow-up deadline 
was January 2014. The survival time was counted from the date of starting definitive 
therapy to the follow-up deadline or date of death, which was primarily caused by carcinoma 
recurrence or metastasis. All patients signed a letter of informed consent approved by our 
Institutional Ethics Committee (no. 1666). 
All specimens were used to extract DNA for HPV detection using the polymerase chain 
reaction (PCR), and we also performed p16 immunohistochemistry. DNA was extracted from 
formalin-fixed, paraffin-embedded (FFPE) tumor specimens using a DNeasy Tissue Kit 
(Qiagen, Valencia, CA, USA). Sixteen HPV genotypes (genotypes 6, 11, 16, 18, 30, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, and 66) were detected by multiple PCR in a single tube. The details 
of the procedures are described elsewhere [14]. We defined the specimen as HPV-positive 
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when both HPV DNA and p16-staining were positive.  
 
Immunohistochemical analysis 
Consecutive 4-μm sections were cut from each block. Immunohistochemical staining 
was performed as described previously [15], [16]. The following primary antibodies were 
used: monoclonal antibodies for SPARC (dilution 1:200; SantaCruz, USA) derived from 
rabbits and p16 (dilution 1:100; SantaCruz, USA) derived from mice. The specificities of 
staining were confirmed using non-immune serum instead of the primary antibodies as 
negative controls. The degree of immunostaining was reviewed and scored independently by 
two observers (S.Y. and N.W.) based on the proportion of positively stained tumor cells and 
intensity of staining. For SPARC evaluation [16], the tumor cell proportion was scored as 
follows: 0 (≤ 5% positive tumor cells), 1 (6–25% positive tumor cells), 2 (26-50% positive 
tumor cells), and 3 (> 51% positive tumor cells). The staining intensity was graded according 
to the following criteria: 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, 
yellow brown), and 3 (strong staining, brown). The staining index (SI) was calculated as the 
product of the staining intensity score and proportion of positive tumor cells, with scores 
from 0 to 9 (0, 1, 2, 3, 4, 6, and 9). The cut-off values for high and low expression levels were 
chosen based on measures of heterogeneity using the log-rank test with respect to overall 
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survival. Optimal cut-off values were defined as follows: SI of ≥ 4 was used to define tumors 
with high SPARC-expression, and SI of ≤ 3 was used to indicate low SPARC-expression. For 




All statistical analyses were conducted using SPSS 19.0 software (IBM, Armonk, NY, 
USA). Data were analyzed using Fisher’s exact t-test. Survival curves were estimated using 
the Kaplan-Meier method, and the log-rank test was used to investigate differences between 
the curves. Multivariate analysis using the Cox proportional hazards regression model was 
carried out to assess the prognostic value of each of the patients’ characteristics. Significance 





Expression of SPARC and p16 in OPSCC tissues (Fig. 1) 
High-expression of SPARC protein was detected in 25 (47.2%) tumors, and 
low-expression was detected in 28 (52.8%) tumors. SPARC protein was mainly localized in 
the cytoplasm of tumor cells and some stromal cells (Fig. 1A, B). Some stromal cells were 
constitutively positive, even if the tumor cells were stained negative (Fig.1C). Twenty-eight 
and twenty-five cases were classified as SPARC-Low (Score 0, 3 cases; Score 1, 1 case; Score 
2, 14 cases; and Score 3, 10 cases) and SPARC-High (Score 4, 2 cases; Score 6, 11 cases; and 
Score 9, 12 cases), respectively. 
The 28 tumors were categorized as p16-positive, among which high-risk HPV-DNA 
was positive in 22 patients (41.5％), all of which were HPV type 16-positive. We confirmed that 
all 22 HPV-DNA-positive tumors were also p16-positive (Fig. 1D). Thus, 22 of the 53 OPSCCs were 
classified as HPV-related OPSCC. 
 
Correlation between patients’ demographic characteristics and the HPV-status (Table 1) 
The HPV-positive and HPV-negative OPSCC patients with respect to several clinical 
features are presented in Table 1. Fifty-three surgical tissues and diagnostic biopsies from 
OPSCC patients, 22 HPV-positive and 31 HPV-negative, were available for our analysis. The 
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mean period of follow-up was 27 months (ranging from 2-100 months). In HPV-positive 
patients, the nodal status had significantly progressed (p = 0.0475). There was no significant 
correlation between the HPV-status and SPARC-expression (P=0.7280).  
 
Correlation between patients’ demographic characteristics and the SPARC-expression 
(Table 2) 
     The SPARC-High and SPARC-Low OPSCC patients with respect to several clinical 
factors are presented in Table 2. No significant correlations were found between any 
analyzed demographic factors. 
Ten out of 28 SPARC-Low patients relapsed, among which 6 patients (60.0%) were 
salvaged by surgery. On the other hand, SPARC-High patients were prone to relapse (14 out 
of 25 patients, 56.0%) and salvage was difficult (only 21.4% of patients were salvaged). 
 
Cox proportional hazards survival analysies (Tables 3, 4) 
Univariate Cox proportional hazards regression analysis revealed that the HPV-status 
and SPARC-expression were significant prognostic indicators in patients with OPSCC in 
terms of the overall survival (OS) (p < 0.05) (Table 3). These two parameters were further 
examined with multivariate analysis. After multivariate adjustment, high 
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SPARC-expression remained a powerful poor prognostic indicator (p = 0.012, HR = 5.125) 
independent of HPV infection (p = 0.021, HR = 0.173).  
Regarding disease-free survival (DFS), univariate Cox proportinal hazards regression 
analysis revealed that the HPV-status and N-factor were significant prognostic indicators of 
DFS (p < 0.05) (Table 4). SPARC-expression was not a significant predictor of DFS. After 
multivariate adjustment, only HPV infection was a significant predictor (p = 0.022, HR = 
0.302) (Table 4).  
 
Survival analyses in HPV-negative and HPV-positive patients in relation to the 
SPARC-expression level (Fig 2) 
     Kaplan-Meier analyses of the 53 OPSCC patients were carried out. OS and DFS were 
determined on the basis of the HPV-status and SPARC-expression. Among all 53 patients, 
the 5-year OS rates differed significantly between HPV-positive and HPV-negative patients 
(Figure 2A; p = 0.011) and between low and high SPARC-expression patients (Figure 2B; p = 
0.006). After stratification by the HPV-status, SPARC-expression remained a significant 
prognostic indicator in HPV-negative OPSCC patients, but was not a significant predictor in 
HPV-positive patients (Figure 2C, D).  
The disease-free survival rate was significantly more favorable in HPV-positive than 
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HPV-negative patients (p = 0.003) (Fig.2E). However, SPARC-expression did not show any 





Higher levels of SPARC-expression have been reported in breast cancer, melanoma, 
and glioblastoma patients [5], [6], [17]. Based on this pattern of expression, one would 
hypothesize a potential role of SPARC in tumor promotion or progression. However, lower 
levels of SPARC-expression have been found in other types of malignancy, such as ovarian, 
colorectal, and pancreatic cancers and acute myelogenous leukemia [8], [9], [18]. This 
pattern of decreased SPARC levels suggests an inhibitory role of SPARC in tumor 
progression. The possible clinical significance of SPARC expression has not been reported in 
OPSCC patients. Therefore, we investigated the relationships between 
immunohistochemical SPARC-expression and clinicopathologic parameters, including 
patient survival. High-expression of SPARC showed a significant correlation with poor OS.  
In OPSCC patients, HPV-infection has accounted for a growing proportion of cases, 
particularly among the middle-aged population. Patients with HPV-positive OPSCC have a 
more favorable prognosis than HPV-negative patients [3]. Our results also support those of 
previous reports. It has been reported that aberrant DNA methylation, an important 
epigenetic mechanism for gene silencing, occurs in HPV-related carcinogenesis [18], and 
that SPARC is transcriptionally down-regulated by its promoter hyper-methylation in some 
cancers. Therefore, we examined the association between the HPV-status and 
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SPARC-expression in OPSCC tissues. However there was no significant correlation between 
the HPV-status and SPARC-expression. Next, we examined whether SPARC could be a 
prognostic indicator in OPSCC patients independent of HPV-infection. Cox proportional 
hazards regression analysis revealed that both SPARC-expression and the HPV-status were 
independent prognostic indicators of OS. In addition, we performed survival analysis of 
HPV-positive and HPV-negative OPSCC patients separately. Generally, HPV-positive 
patients show more favorable survival. Thus, the sample size of the patients involved in this 
study was not sufficient to yield a significant difference. Among HPV-negative OPSCC 
patients, the cumulative OS rate of patients with low SPARC-expression was significantly 
better than in those high expression. Thus, SPARC-expression may be an indicator of a 
favorable prognosis among HPV-negative OPSCC patients.  
In contrast to OS, SPARC-expression did not show a significant correlation with DFS. 
The reason why SPARC-expression was not a prognostic indicator of DFS is considered to be 
that SPARC-High patients were inoperable at the time of relapse or could not be rescued by 
salvage surgery. In other words, SPARC-Low patients could be salvaged, so their OS rate 
was higher than that of SPARC-High patients. It has been reported that SPARC regulates 
cell-ECM signals which control cell invasion and migration [19], and the formation of matrix 





SPARC-expression is an indicator of the prognosis in terms of OS independent of 
HPV-infection. HPV-negative patients with low SPARC-expression show survival as 
favorably as HPV-positive patients probably because of their higher salvage rate after 
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Figure 1 Immunohistochemical detection of SPARC (A, B, and C) and p16 (D) proteins in 
OPSCC tumors (original magnification, 100x). A and B, SPARC protein was 
immunolocalized in the cytoplasm of tumor cells. Some stromal cells were also positive. C, 
Some stromal cells were constitutively positive, even if the tumor cells were stained negative. 
D, p16 protein expression was evaluated as positive only when diffuse immunoreactivity 
was observed in the tumor cell nest. 
 
Figure 2 Kaplan-Meier survival curve of overall survival (OS) and disease-free survival 
(DFS) and log-rank test for patients with a different HPV-status and SPARC-expression 
levels. A, The 5-year OS rate was significantly different between the HPV-positive and 
HPV-negative OPSCC patients (p = 0.011). B, The 5-year OS rate was significantly different 
between SPARC-Low and SPARC-High patients (p = 0.006). C, Within the HPV-positive 
stratum, SPARC-expression did not show a significant effect on OS (p = 0.137). D, Within 
the HPV-negative stratum, the SPARC-Low patients showed significantly more favorable 
OS than the SPARC-High patients (p = 0.014). E, The DFS curve of OPSCC patients with a 
different HPV-status was significantly different between HPV-positive and HPV-negative 
patients (p = 0.003). F, The DFS curve with different SPARC-expression levels did not show 
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a significant difference (p = 0.157). G and H, In both the HPV-positive and HPV-negative 
stratum, SPARC-expression did not show any significant correlation with DFS (p = 0.182 
and p = 0.420). 
Characteristics Total HPV-positive HPV-negative p
No. of cases 53 22 31
Sex
Male 49 20 29 > 0.9999
Female 4 2 2
Age at Diagnosis
Median 62 61 62 0.8490
Range 39-89 39-89 45-85
Mean 63.7 63.7 63.7
Staging
T1-2 34 15 19 0.7725
T3-4 19 7 12
N0 21 5 16 0.0475
N1-3 32 17 15
I-II 13 4 9 0.5199
III-IV 40 18 22
Smoking history
Smoker 41 15 26 0.2018
Non-smoker 12 7 5
Treatment
Surgery±Radiation 20 7 13 0.5689
Radiation±Chemotherapy 33 15 18
SPARC
High 25 11 14 0.7850
Low 28 11 17
Table 1. Correlation between patients' characteristics and HPV-status
HPV, human papillomavirus; SPARC, secreted protein acidic and rich in cysteine.
Smoker is defined as a patient with smoking history.  Non-smoker is defined 
as a patient without any history of smoking.
Characteristics Total SPARC-High SPARC-Low p
No. of cases 53 25 28
Sex
Male 49 23 26 > 0.9999
Female 4 2 2
Age at Diagnosis
Median 62 66 60.5 0.1808
Range 39-89 39-89 48-81
Mean 63.7 65.2 62.4
Staging
T1-2 34 17 17 0.7748
T3-4 19 8 11
N0 21 9 12 0.7793
N1-3 32 16 16
I-II 13 7 6 0.7508
III-IV 40 18 22
Smoking history
Smoker 41 17 24 0.1896
Non-smoker 12 8 4
Treatment
Surgery±Radiation 20 6 14 0.0876
Radiation±Chemotherapy 33 19 14
HPV
positive 22 11 11 0.7280
negative 31 14 17
Table 2. Correlation between patients' characteristics and SPARC-expression
HPV, human papillomavirus; SPARC, secreted protein acidic and rich in cysteine.
Smoker is defined as a patient with smoking history.  Non-smoker is defined 
as a patient without any history of smoking.
HR (95% CI) p HR (95% CI) p
Age (≧62 vs. <62) 1.016 (0.368-2.806) 0.976
Sex (Male vs. Female) 1.741 (0.224-13.565) 0.596
Smoking history (Smoker vs Non-smoker) 1.095 (0.343-3.497) 0.878
T factor (T3,4 vs. T1,2) 2.068 (0.717-5.963) 0.179
N factor (N1-3 vs. N0) 0.546 (0.198-1.511) 0.244
Stage (III,IV vs. I,II) 1.411 (0.396-5.026) 0.595
Therapy (Radiation vs. Surgery) 2.501 (0.705-8.864) 0.156
HPV (Positive vs. Negative) 0.181 (0.041-0.805) 0.025 0.173 (0.039-0.769) 0.021
SPARC (High vs. Low) 4.911 (1.277-17.516) 0.014 5.125 (1.437-18.276) 0.012
Univariate analysis Multivariate analysisCharacteristics
Overall survival
Table 3. Overall survival analyses using univariate and multivariate Cox proportional hazards model
HPV, human papillomavirus; SPARC, secreted protein acidic and rich in cysteine.
HR (95% CI) p HR (95% CI) p
Age (≧62 vs. <62) 1.245 (0.557-2.784) 0.593
Sex (Male vs. Female) 3.102 (0.415-23.203) 0.270
Smoking history (Smoker vs Non-smoker) 1.366 (0.510-3.650) 0.535
T factor (T3,4 vs. T1,2) 1.323 (0.584-2.999) 0.502
N factor (N1-3 vs. N0) 0.378 (0.169-0.843) 0.018 0.480 (0.211-1.094) 0.081
Stage (III,IV vs. I,II) 0.621 (0.267-1.443) 0.268
Therapy (Radiation vs. Surgery) 0.905 (0.405-2.019) 0.807
HPV (Positive vs. Negative) 0.257 (0.095-0.694) 0.007 0.302 (0.109-0.839) 0.022
SPARC(High vs. Low) 1.744 (0.781-3.895) 0.175
Univariate analysis Multivariate analysisCharacteristics
HPV, human papillomavirus; SPARC, secreted protein acidic and rich in cysteine.
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